Income Taxes	9 Months Ended
Sep. 30, 2011
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In the first quarter of 2010, the Patient Protection and Affordable Care Act (“PPACA”) was signed into law. The PPACA changed the tax treatment related to an existing retiree drug subsidy (“RDS”) available to sponsors of retiree health benefit plans that provide a benefit that is at least actuarially equivalent to the benefits under Medicare Part D. As a result of the PPACA, RDS payments will effectively become taxable in tax years beginning in 2013 by requiring the amount of the subsidy received to be offset against the Company’s deduction for health care expenses. Accordingly, during the first quarter of 2010, the Company recorded a one time charge to income tax expense of $1,021,000 related to the write down of its deferred tax asset for RDS. The Company’s consolidated balance sheets at September 30, 2011 and December 31, 2010 include a net deferred tax asset of $3,951,694 and $3,910,495, respectively. The Company performs analyses to evaluate the balance of deferred tax assets that will be realized. Such analyses are based on the premise that the Company is, and will continue to be, a going concern and that it is more likely than not that deferred tax benefits will be realized through the generation of future taxable income. Income tax expense for the nine months ended September 30, 2011 is estimated to be $4,388,742, or 36% of income before income taxes. Income tax expense for the nine months ended September 30, 2010 was estimated to be $1,876,245, or 75% of income before income taxes. Excluding the write down of the aforementioned deferred tax asset for RDS, the Company’s effective tax rate was estimated to be 34% for the nine months ended September 30, 2010. Income tax expense for the nine months ended September 30, 2011 included $105,000 of interest and penalties related to Mexican income tax filings. No such costs were included in income tax expense for the same period in 2010. The Company follows accounting guidance related to uncertainty in income taxes. As of September 30, 2011, the Company had no liability for unrecognized tax benefits under this guidance. The Company does not anticipate that the unrecognized tax benefits will significantly change within the next twelve months. The Company files income tax returns in the U.S. federal jurisdiction, Mexico and various state jurisdictions. The Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for the years before 2008, and no longer subject to Mexican income tax examinations by Mexican authorities for the years before 2006. The Company's 2009 Mexican income tax return is currently under audit by Mexican tax authorities.

Income Taxes

9 Months Ended

Sep. 30, 2011

In the first quarter of 2010, the Patient Protection and Affordable Care Act (“PPACA”) was signed into law. The PPACA changed the tax treatment related to an existing retiree drug subsidy (“RDS”) available to sponsors of retiree health benefit plans that provide a benefit that is at least actuarially equivalent to the benefits under Medicare Part D. As a result of the PPACA, RDS payments will effectively become taxable in tax years beginning in 2013 by requiring the amount of the subsidy received to be offset against the Company’s deduction for health care expenses. Accordingly, during the first quarter of 2010, the Company recorded a one time charge to income tax expense of $1,021,000 related to the write down of its deferred tax asset for RDS.

The Company’s consolidated balance sheets at September 30, 2011 and December 31, 2010 include a net deferred tax asset of $3,951,694 and $3,910,495, respectively. The Company performs analyses to evaluate the balance of deferred tax assets that will be realized. Such analyses are based on the premise that the Company is, and will continue to be, a going concern and that it is more likely than not that deferred tax benefits will be realized through the generation of future taxable income.

Income tax expense for the nine months ended September 30, 2011 is estimated to be $4,388,742, or 36% of income before income taxes. Income tax expense for the nine months ended September 30, 2010 was estimated to be $1,876,245, or 75% of income before income taxes. Excluding the write down of the aforementioned deferred tax asset for RDS, the Company’s effective tax rate was estimated to be 34% for the nine months ended September 30, 2010. Income tax expense for the nine months ended September 30, 2011 included $105,000 of interest and penalties related to Mexican income tax filings. No such costs were included in income tax expense for the same period in 2010.

The Company follows accounting guidance related to uncertainty in income taxes. As of September 30, 2011, the Company had no liability for unrecognized tax benefits under this guidance. The Company does not anticipate that the unrecognized tax benefits will significantly change within the next twelve months.

The Company files income tax returns in the U.S. federal jurisdiction, Mexico and various state jurisdictions. The Company is no longer subject to U.S. federal and state income tax examinations by tax authorities for the years before 2008, and no longer subject to Mexican income tax examinations by Mexican authorities for the years before 2006. The Company's 2009 Mexican income tax return is currently under audit by Mexican tax authorities.